PMID- 33663074
OWN - NLM
STAT- MEDLINE
DCOM- 20210316
LR  - 20230905
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 8
DP  - 2021 Feb 26
TI  - Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes 
      in patients with type 2 diabetes mellitus and chronic kidney disease: A protocol 
      for systematic review and meta-analysis.
PG  - e24655
LID - 10.1097/MD.0000000000024655 [doi]
LID - e24655
AB  - BACKGROUND: Many studies have shown the effects of SGLT2 inhibitors on type 2 
      diabetes, but the effects in patients with type 2 diabetes with chronic kidney 
      disease remains unclear. This study aims to evaluate the effects of SGLT2 
      inhibitors on renal outcomes in patients with type 2 diabetes mellitus with 
      chronic kidney disease. METHODS: We conducted systematic searches of PubMed, 
      Embase, and Cochrane Central Register of Controlled Trials up to April 30, 2020 
      and included randomized controlled trials of SGLT2 inhibitors in adult type 2 
      diabetes mellitus (T2DM) patients with chronic kidney disease (CKD) reporting 
      estimated glomerular filtration rate (eGFR) and/or urine albumin/creatinine ratio 
      (UACR) changes and/or acute kidney injury or failure (AKI). Random effects models 
      were adopted to measure the pooled outcomes. RESULTS: Nine studies with 8826 
      participants were included. SGLT2 inhibitors were not associated with a 
      significant change in eGFR (mean difference (MD), -0.75 ml/minutes per 1.73 m2, 
      95% CI -1.61 to 0.10, P = .09) in type 2 diabetic patients with CKD. UACR 
      reduction after SGLT2 inhibitors was significant in type 2 diabetic patients with 
      CKD (MD -24.27 mg/g, 95% CI -44.46 to -4.09, P = .02). SGLT2 inhibitors 
      associated with AKI in the patients were significant (OR 0.80, 95% CI [0.66 to 
      0.98], P = .03). CONCLUSION: SGLT2 inhibitors had no significant effect on kidney 
      function (eGFR measured) in the pooled analysis. And SGLT2 inhibitors effectively 
      reduced UACR in T2DM with CKD. Besides, SGLT2 inhibitors could reduce the 
      incidence of AKI.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Yu, Baisong
AU  - Yu B
AUID- ORCID: 0000-0002-8915-422
AD  - Department of Nephrology, Hebei General Hospital, Shijiazhuang, Hebei, China.
FAU - Dong, ChunXia
AU  - Dong C
FAU - Hu, ZhiJuan
AU  - Hu Z
FAU - Liu, Bing
AU  - Liu B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Albuminuria
MH  - Creatinine/blood
MH  - Diabetes Mellitus, Type 2/*drug therapy/*epidemiology
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Kidney Function Tests
MH  - Randomized Controlled Trials as Topic
MH  - Renal Insufficiency, Chronic/*epidemiology
MH  - Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
MH  - Meta-Analysis as Topic
MH  - Systematic Review as Topic
PMC - PMC7909223
COIS- The authors have no conflicts of interests to declare.
EDAT- 2021/03/06 06:00
MHDA- 2021/03/17 06:00
PMCR- 2021/02/26
CRDT- 2021/03/05 01:00
PHST- 2020/08/08 00:00 [received]
PHST- 2021/01/08 00:00 [accepted]
PHST- 2021/03/05 01:00 [entrez]
PHST- 2021/03/06 06:00 [pubmed]
PHST- 2021/03/17 06:00 [medline]
PHST- 2021/02/26 00:00 [pmc-release]
AID - 00005792-202102260-00037 [pii]
AID - MD-D-20-07888 [pii]
AID - 10.1097/MD.0000000000024655 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Feb 26;100(8):e24655. doi: 
      10.1097/MD.0000000000024655.